---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-017418"
form_type: "8-K"
ticker: "NXTC"
cik: "0001661059"
company_name: "NextCure, Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:32:33.827592+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# NextCure Q3 2023 net loss $14.3M vs $18.9M YoY; cash $118.2M funds into mid-2025

## Summary
- Cash and securities $118.2M at Sep 30 2023, down $41.7M from Dec 31 2022; expects funding into mid-2025.
- Net loss $14.3M for Q3 2023 vs $18.9M for Q3 2022; narrowed loss due to lower R&D and G&A costs.
- R&D expenses $11.0M (down from $13.5M); G&A $4.6M (down from $5.7M).
- Phase 1b updates for NC410 and NC762, and NC525 Phase 1a update expected by year end 2023.
- Selected LNCB74 (B7-H4 ADC) from LegoChem collaboration; presented data on NC605 and NC181.

## SEC filing metadata
- accession: 0001558370-23-017418
- form_type: 8-K
- ticker: NXTC
- cik: 0001661059
- company_name: NextCure, Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661059/000155837023017418/0001558370-23-017418-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661059/000155837023017418/nxtc-20231102x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-017418
- JSON: https://secwatch.observer/filing/0001558370-23-017418.json
- Plain text: https://secwatch.observer/filing/0001558370-23-017418.txt

## Key facts
- Earnings Releases
  NextCure, Inc. reported quarter ended September 30, 2023 results: net income Net loss was $14.3 million for the quarter ended September 30, 2023.
  - Period: quarter ended September 30, 2023
  - Net income: Net loss was $14.3 million for the quarter ended September 30, 2023
  - Result: reported results
  source text: NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661059/000155837023017418/0001558370-23-017418-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.